ArticleTransboundary and emerging diseases2025
Attenuation Profile and Molecular Characterization of a High-Passaged Attenuated Getah Virus Strain.
Article in Transboundary and emerging diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Isolation and Characterization of a Highly Virulent Getah Virus Causing Acute Lethal Infection in Neonatal Piglets.Transboundary and emerging diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, the prevalence of epizootic diseases caused by Getah virus (GETV) has surged in China, raising significant concerns for animal health and posing a potential threat to public health. This study aims to systematically compare the phenotypic and genotypic characteristics of a high-passage attenuated GETV strain (HuN1-P230) with its virulent parental strain (HuN1), elucidating the molecular changes associated with the attenuation process. The HuN1-P230 strain exhibited enhanced replication kinetics, higher viral titers, and a small-plaque phenotype in cell cultures compared to HuN1. Notably, pregnant mice inoculated with HuN1-P230 displayed a 100% survival rate among neonates, in stark contrast to the complete absence of live births observed with the parental HuN1 strain, indicating a highly attenuated virulence phenotype. Furthermore, challenge experiments demonstrated that HuN1-P230 conferred complete protection against the virulent HuN1 strain. Genomic comparative analysis revealed that HuN1-P230 harbored 26 nucleotide mutations relative to HuN1, including 11 silent mutations and 15 amino acid substitutions. Structural analysis of the GETV spike protein indicated that the observed antigenic differences were closely linked to amino acid substitutions located on the viral surface. These findings suggest that the phenotypic changes observed during GETV attenuation are closely associated with specific genetic modifications, providing critical insights into the molecular mechanisms underlying viral attenuation and highlighting the potential of HuN1-P230 as a vaccine candidate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.